BENGALURU, India –

Novavax Inc mentioned on Wednesday facts from research in grown ups and adolescents confirmed that the booster dose of its COVID-19 vaccine generated robust antibodies towards several Omicron variants, which include BA.1, BA.2 and BA.5.

The information was from two research — a late-stage examine analyzing the booster in adults and adolescents who had obtained Novavax major vaccination and a further examine tests it in those people aged 18 to 49 who experienced received major collection of Novavax vaccine or other authorized or approved vaccines.

In the late-phase study, a one homologous booster dose substantially enhanced antibody concentrations versus these variants relative to pre-raise amounts, the company said.

“These information are an early sign that our vaccine may possibly be effective from variants these types of as Omicron,” Novavax government Gregory M. Glenn reported.

The corporation claimed ongoing trials are finding out the efficacy of the vaccine in opposition to variants together with BA.4 and BA.5.
